Adenocarcinoma of the prostate is the second-most common malignant tumor in the male population. The fifth edition of the WHO Classification of the Urinary and Male Genital Systems focuses on recent data regarding various prognostic factors in the context of histopathology.
Some of the most significant updates include:
(1) Clear differentiation between ductal carcinoma and PIN-like prostate adenocarcinoma, with the latter now defined as a subtype of acinar adenocarcinoma;
(2) Using the “AIP” terminology in biopsies that are inconclusive of IDC-P versus HGPIN;
(3) Discussion of the histopathological features of the treatment-related neuroendocrine carcinoma of the prostate gland in its own separate section in the prostate cancer chapter;
(4) Accent is put on the cribriform morphological pattern as it is related to much worse prognosis than the other Gleason pattern 4’s;
(5) The newest recommendations for the forming of the Gleason score are presented and a detailed comparison between the ISUP’s and GUPS’s approach is made to in order to define tertiary Gleason pattern.
Some of the data is inconclusive and requires further extensive research.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428–11436.
Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014; 12:719–726.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment‐emergent small‐cell neuroendocrine prostate cancer: a multi‐institutional prospective study. J Clin Oncol. 2018; 36(24):2492–2503.
Aydin H, Zhang J, Samaratunga H. Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU Int. 2010; 105:476-480.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration‐resistant neuroendocrine prostate cancer. Nat Med. 2016; 22(3):298–305.
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway‐independent prostate cancer is sustained through FGF signaling. Cancer Cell 2017; 32(4):474–489.e6.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer 2019; 121:7–18.
Eble JNSG, Epstein JI, Sesterhenn IA. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004.
Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M. Contemporary prognostic indicators for prostate cancer incorporating international society of urological pathology recommendations. Pathology 2018; 50:60–73.
Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006; 175(3 Pt 1):820-834.
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756–767.
Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. 2021; 145(4):461–493.
Hesterberg AB, Gordetsky JB, Hurley PJ. Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations. Urology. 2021; 155:47-54.
Hickman RA, Yu H, Li J, Kong M, Shah RB, Zhou M, et al. Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol. 2017; 41(4):550–556.
IARC. WHO. Data visualization tools for exploring the global cancer burden in 2020. Access date December 2022.
Iczkowski KA, Paner GP, van der Kwast T. The New Realization About Cribriform Prostate Cancer. Adv Anat Pathol. 2018; 25:31-37.
Kaur HB, Salles DC, Paulk A, Epstein JI, Eshleman JR, Lotan TL. PIN‐like ductal carcinoma of the prostate has frequent activating ras/raf mutations. Histopathology 2021; 78:327–333.
Kweldam CF, van der Kwast T, van Leenders GJ. On cribriform prostate cancer. Transl Androl Urol. 2018; 7:145-154.
Lee TK, Ro JY. Spectrum of Cribriform Proliferations of the Prostate: From Benign to Malignant. Arch Pathol Lab Med. 2018; 142:938-946.
Moch HHP, Ulbright TM, Reuter V. The WHO classification of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2016.
Montironi R, Cimadamore A, Gasparrini S. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev Anticancer Ther. 2018; 18:685-693.
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment‐related neuroendocrine prostate cancer. Neoplasia 2013; 15(1):1–10.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in tp53‐ and rb1‐deficient prostate cancer. Science 2017; 355(6320):84–88.
Netto GJ, Amin MB, Kench JG et al. Chapter 4: Tumours of the prostate. In: Srigley JR, Amin MB, Rubin MA, Tsuzuki T, eds. WHO classification of tumours: Urinary and male genital tumours. Lyon, France: International Agency for Research on Cancer; 2022.
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 2018; 362(6410):91–95.
Paulk A, Giannico G, Epstein JI. PIN‐like (ductal) adenocarcinoma of the prostate. Am J Surg Pathol. 2018; 42:1693–1700.
Priemer DS, Montironi R, Wang L, Williamson SR, Lopez‐Beltran A, Cheng L. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification. Endocr Pathol. 2016; 27:123–135.
Rubin MA, Bristow RG, Thienger PD, Dive C, Imielinski M. Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers. Mol Cell 2020; 80:562–577.
Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L, et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 2014; 1846(2):630–637.
Seipel AH, Delahunt B, Samaratunga H. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology. 2016; 48:398-405.
Shah RB, Yoon J, Liu G, Tian W. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology 2017; 71:693–702.
Shah RB, Nguyen JK, Przybycin CG, Reynolds JP, Cox R, Myles J, et al. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology 2019; 75(3):346–353.
Shehabeldin AN, Ro JY. Neuroendocrine tumors of genitourinary tract: recent advances. Ann Diagn Pathol. 2019; 42:48–58.
Tavora F, Epstein JI. High‐grade prostatic intraepithelial neoplasia like ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol. 2008; 32:1060–1067.
Truong M, Frye T, Messing E. Historical and contemporary perspectives on cribriform morphology in prostate cancer. Nat Rev Urol. 2018; 15:475-482.
Van de Kwast TH, Kristiansen G, McKenney JK. WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. IARC Press: Lyon (France); 2022.
van Leenders GJLH, van der Kwast TH, Grignon DJ. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020; 44(8):e87-e99.
Varma M. Intraductal carcinoma of the prostate: a guide for the practicing pathologist. Adv Anat Pathol. 2021; 28:276–287.
Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from nepc diagnosis‐a systematic review and pooled analysis. J Clin Oncol. 2014; 32:3383–3390.
Zhou M, Netto GJ, Fine SW. WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. IARC Press: Lyon (France); 2022.
